Vascular Biogenics Ltd. [NASDAQ: VBLT] loss -79.27% on the last trading session, reaching $0.43 price per share at the time. The company report on July 19, 2022 that VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer.
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
– Trial Did Not Meet Statistical Significance on Improvement in Primary Endpoints of Progression Free Survival (PFS) or Overall Survival (OS) -.
VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced top-line data from the Phase 3 OVAL clinical trial of ofra-vec (ofranergene obadenovec; VB-111) in platinum-resistant ovarian cancer. The trial did not meet the primary endpoints of achieving a statistically significant improvement in progression-free survival (PFS) or overall survival (OS).
Vascular Biogenics Ltd. represents 77.39 million in outstanding shares, while the company has a total market value of $26.52 million with the latest information. VBLT stock price has been found in the range of $0.40 to $0.4777.
If compared to the average trading volume of 228.34K shares, VBLT reached a trading volume of 28067463 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Vascular Biogenics Ltd. [VBLT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VBLT shares is $5.30 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VBLT stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Vascular Biogenics Ltd. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on July 20, 2022. The new note on the price target was released on July 20, 2022, representing the official price target for Vascular Biogenics Ltd. stock. Previously, the target price had yet another raise to $5.50, while Oppenheimer analysts kept a Outperform rating on VBLT stock.
The Average True Range (ATR) for Vascular Biogenics Ltd. is set at 0.25, with the Price to Sales ratio for VBLT stock in the period of the last 12 months amounting to 37.88. The Price to Book ratio for the last quarter was 0.77, with the Price to Cash per share for the same quarter was set at 0.71.
Trading performance analysis for VBLT stock
Vascular Biogenics Ltd. [VBLT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -78.64. With this latest performance, VBLT shares dropped by -68.75% in over the last four-week period, additionally sinking by -73.10% over the last 6 months – not to mention a drop of -82.79% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VBLT stock in for the last two-week period is set at 23.23, with the RSI for the last a single of trading hit 17.53, and the three-weeks RSI is set at 27.67 for Vascular Biogenics Ltd. [VBLT]. The present Moving Average for the last 50 days of trading for this stock 1.60, while it was recorded at 1.70 for the last single week of trading, and 1.75 for the last 200 days.
Vascular Biogenics Ltd. [VBLT]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Vascular Biogenics Ltd. [VBLT] shares currently have an operating margin of -3905.73 and a Gross Margin at -111.07. Vascular Biogenics Ltd.’s Net Margin is presently recorded at -3895.83.
Return on Equity for this stock declined to -72.01, with Return on Assets sitting at -56.26.
Vascular Biogenics Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.20 and a Current Ratio set at 4.20.
An analysis of insider ownership at Vascular Biogenics Ltd. [VBLT]
There are presently around $13 million, or 20.50% of VBLT stock, in the hands of institutional investors. The top three institutional holders of VBLT stocks are: LION POINT CAPITAL, LP with ownership of 2,593,286, which is approximately 0% of the company’s market cap and around 23.95% of the total institutional ownership; PHOENIX HOLDINGS LTD., holding 1,020,000 shares of the stock with an approximate value of $2.09 million in VBLT stocks shares; and IKARIAN CAPITAL, LLC, currently with $1.7 million in VBLT stock with ownership of nearly 5.046% of the company’s market capitalization.
Positions in Vascular Biogenics Ltd. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 12 institutional holders increased their position in Vascular Biogenics Ltd. [NASDAQ:VBLT] by around 273,237 shares. Additionally, 8 investors decreased positions by around 97,273 shares, while 9 investors held positions by with 6,023,631 shares. The mentioned changes placed institutional holdings at 6,394,141 shares, according to the latest SEC report filing. VBLT stock had 5 new institutional investments in for a total of 76,701 shares, while 4 institutional investors sold positions of 33,341 shares during the same period.